CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

Lectins: Are These Food-Based Proteins Friend or Foe?

Published: Fri, 17 Aug 2018 12:09:27 EDT
With limited data or logic to back them up, lectins are now under scrutiny.
Medscape

AI System Accurately Detects 53 Kinds of Eye Disease

Published: Fri, 17 Aug 2018 11:12:17 EDT
In 'jaw-dropping' trial results, researchers find that an artificial intelligence system was as effective as some of the world's best eye experts in spotting diseases that could lead to blindness.
Medscape Medical News

Triggers of Takotsubo Syndrome Point to Differing Prognoses

Published: Fri, 17 Aug 2018 11:11:36 EDT
A new study finds unique differences in survival but also raises questions about how best to classify these patients and why so many have no identifiable triggering event.
Medscape Medical News
Displaying results 7-9 (of 20)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

HEALTHCARE SUPPLIER NEWS

Too scared to speak in public? Biohaven says it has a drug that can help

Published: Thu, 16 Aug 2018 12:59:23 +0000
Biohaven’s new formulation of amyotrophic lateral sclerosis drug riluzole has helped people with social anxiety face the challenge of speaking in public.

Regeneron, Teva’s pain drug clears phase 3 efficacy bar

Published: Thu, 16 Aug 2018 12:44:56 +0000
A phase 3 osteoarthritis trial of Teva and Regeneron’s fasinumab has met its co-primary endpoints. The anti-NGF antibody cleared the efficacy bar but triggered the expected safety alarms, keeping it on the tail of Pfizer and Eli Lilly’s rival asset without dispelling doubts about its prospects.

Pfizer pays BioNTech $120M upfront to form mRNA flu vaccine pact

Published: Thu, 16 Aug 2018 10:05:54 +0000
Pfizer has struck a $425 million deal to work with BioNTech on the development of mRNA influenza vaccines. The Big Pharma is providing $120 million in upfront and near-term payments to enter into the R&D collaboration.
Displaying results 7-9 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

 Security code
1-800-4-the-clinx

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top